Canagliflozin is an SGLT2 inhibitor that has been shown to lead to better glycemic control and greater weight loss than dipeptidyl peptidase-4 (DPP4) inhibitors in patients with T2D on background metformin monotherapy [7] or metformin plus sulfonylureas [8]. Here, SLC5A2 is linked to type 2 diabetes mellitus.